#Germany #Düsseldorf #Neuraxpharm #mjn-neuro #EPISERAS

Neuraxpharm and mjn-neuro Set to Transform Epilepsy Care with EPISERAS®

In a significant advance for epilepsy management, Neuraxpharm, a renowned European pharmaceutical company, has announced a collaboration with mjn-neuro to introduce EPISERAS®, a cutting-edge digital health solution. This innovative technology, designed to enhance the safety and quality of life for individuals living with epilepsy, consists of a non-invasive, AI-powered wearable earpiece that continuously monitors brain activity to detect seizure risks in real time.

The device operates discreetly, analyzing electrical patterns in the brain and sending alerts to users and their caregivers just minutes before a seizure is expected. This advance could shift how those with epilepsy manage their daily lives, offering peace of mind and the ability to take preventative action.

A New Era in Epilepsy Management

EPISERAS® symbolizes a departure from traditional treatments focused solely on medication. Instead, it represents Neuraxpharm's commitment to integrating technology into healthcare, emphasizing a holistic approach that prioritizes not just pharmacological interventions but also lifestyle management through digital solutions.

The wearable device connects to a dedicated mobile app that processes and displays critical seizure-risk information, empowering patients to monitor their conditions effectively. This proactive tool is particularly crucial for individuals with drug-resistant epilepsy, who face heightened risks of accidents due to unforeseen seizures.

In addition to being recognized as a Class IIa medical device — validated for use within Europe under both the CE and UKCA certifications — the technology is underpinned by rigorous clinical research. The ongoing SERAS-Home_RWD study, participants from Spain, the UK, and Germany are contributing valuable data which will substantiate the efficacy of the EPISERAS® system.

Words from the Innovators

Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, expressed the company’s determination to enhance the lives of individuals with central nervous system (CNS) disorders. He remarked on the significance of this technology in advancing epilepsy management, saying, "This breakthrough embodies our commitment to digital personalized CNS care, helping patients feel safer and more in control."

Similarly, David Blánquez, co-founder of mjn-neuro, reflects on the decade-long journey to bring this innovation to life. He emphasizes the importance of making this technology accessible to patients who will benefit from it the most, further stating, "This medical digital solution will significantly minimize seizure-related accidents and promote a better quality of life."

Concluding Thoughts

With EPISERAS® set to launch in Europe in late 2026, Neuraxpharm reinforces its leadership in the epilepsy treatment sector. By combining advanced AI technology with practical, patient-centered design, EPISERAS® is positioned to make a profound impact on the standard of care for epilepsy, aligning with Neuraxpharm's broader vision of comprehensive CNS care that enhances both safety and autonomy for patients. The collaboration with mjn-neuro not only showcases the potential of digital health solutions but sets a new standard for innovation in medical devices. This initiative paves the way for further developments targeting neurological diseases with personalized technology in the foreseeable future.